Dr. Jacques Bradwejn is Dean emeritus of the Faculty of Medicine at the University of Ottawa. He trained in medicine at the University of Sherbrooke and in psychiatry at McGill University and completed a research fellowship in psychopharmacology at McGill University and in neuropsychopharmacology at the University of Montreal. Dr. Bradwejn has also completed the Wharton Certificate of Professional Development at the Wharton School, University of Pennsylvania and has been a member of the Wharton Fellows Program. Before serving as Dean, Dr. Bradwejn served as Chair of the Department of Psychiatry of the University of Ottawa and as Psychiatrist-in-Chief at the Royal Ottawa Hospital, positions he has held since January 1998, and as Head of Psychiatry of The Ottawa Hospital since January 1999. He has also held positions at McGill University as Associate Professor of Psychiatry and at the University of Toronto as Professor of Psychiatry.
Dr. Bradwejn has been actively involved in psychiatric and mental health research. His main research interest has been in the field of anxiety disorders for which he gained an international reputation. He was the first to hypothesize a role for the neuropeptide cholecystokinin (CCK) in the etiology of panic attacks in humans. He h also carries out research on the integration of biological and psychological approaches in the treatment of anxiety disorders and to approaches used by Complementary Medicines. He has published over 170 articles and book chapters, has made more than 400 scientific and educational conferences and over 350 educational media interventions.
Dr. Bradwejn was Chair of the Board of Directors of the Association of Faculties of Medicine of Canada (AFMC), from 2012 to 2014. He was recently appointed as Visiting Professor at the Shanghai Jiao Tong University School of Medicine where he established with his Shanghai partners the Ottawa Shanghai Joint School of Medicine at Renji Hospital.